Biotech firm Compugen Ltd. announced today that their "novel peptide antagonist" called CGEN-25007 was shown to reduce IBD-type inflammation in mice.
Apparently they induce colitis in the mice and then treat some of them with the peptide agent and some without. The mice who were given the CGEN-25007 got better while the other mice suffered wasting disease. (Poor mice!)
Here is a quote from the press release about Compugen's new drug agent:
These results suggest that
CGEN-25007 could have a potential therapeutic utility to treat IBD and
other autoimmune diseases with a strong inflammatory component, such as
rheumatoid arthritis.
